Objectives: Increased transparency with regard to how Central Nervous System (CNS) medication - with a particular emphasis on Depression - is assessed throughout the reimbursement process has several benefits: justifies for previous decisions, may influence reflection on patients needs and gives clear market access criteria for manufacturers. Our objective was to highlight the level of transparency of Drugs used to treat Depression in some European countries: Hungary, Romania as well as neighboring areas such as Turkey and CIS. Methods: We evaluated HTA process for Drugs used to treat Depression (or in general CNS drugs) against a pre-defined scorecard of transparency. Information was obtained from public sources: websites of governmental institutions and official legislations. Evaluation was made on the following six elements: requirements for reimbursement, availability of submitted documents by manufacturers, process of the submissions evaluation or appraisal, recommendations by those who conducted evaluation, final reimbursement decision, follow-up on decisions. Results: In Hungary an HTA guideline and a critical appraisal checklist are available to draw up the basic requirements for reimbursement submissions. However, apart from the final decision no other transparency element is available. In Romania, he current general legislation provides clear timelines and evaluation criteria, in reality, the deadlines are not met. Criteria for evaluation are clearly mentioned in the legislation, but a more clear guidance is still required. In Turkey and CIS, the overall legislation provides clear information for the P&R process. Conclusions: Even if important steps in providing a clear and transparent HTA process for CNS drugs had been established in the legislative framework of the different countries, many areas require improvement. This could be done through clear published submission timeline, closing the gap between evaluation process and actual reimbursement, functional appealing committee and objective criteria are still missing in key points of the evaluation process.